Champions Oncology (CSBR) Non-Current Deffered Revenue (2018 - 2019)
Champions Oncology (CSBR) posted quarterly Non-Current Deffered Revenue of $851000.0 for Q2 2019, up 87.44% year-over-year from $454000.0 in Q2 2018, and up 16.1% quarter-over-quarter from $733000.0 in Q1 2019.
Champions Oncology (CSBR) Non-Current Deffered Revenue (2018 - 2019) Analysis & Trends
Champions Oncology's Non-Current Deffered Revenue history runs 2 years deep, the most recent figure standing at $851000.0 for Q2 2019.
- In Q2 2019, Non-Current Deffered Revenue rose 87.44% year-over-year to $851000.0; the TTM figure through Apr 2019 stood at $851000.0 (up 87.44% YoY), while the FY2019 annual figure was $851000.0, up 87.44% from the prior year.
- Non-Current Deffered Revenue for Q2 2019 stood at $851000.0, up from $733000.0 in the prior quarter.
- The five-year high for Non-Current Deffered Revenue was $851000.0 in Q2 2019, with the low at $454000.0 in Q2 2018.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Non-Current Deffered Revenue (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 139.13 Bn | 131.28 Bn | 2.84 Bn | - |
| 2 | Regeneron Pharmaceuticals | 85.77 Bn | 77.77 Bn | 3.93 Bn | 220.40 Mn |
| 3 | Argenx Se | 64.64 Bn | 59.46 Bn | 1.37 Bn | - |
| 4 | Moderna | 58.29 Bn | 53.16 Bn | 52.00 Mn | 147.00 Mn |
| 5 | BeOne Medicines | 41.92 Bn | 36.82 Bn | 1.53 Bn | - |
| 6 | Alnylam Pharmaceuticals | 31.58 Bn | 28.28 Bn | 992.69 Mn | - |
| 7 | BioNTech SE | 28.12 Bn | 9.73 Bn | 668.28 Mn | - |
| 8 | Insmed | 27.39 Bn | 26.22 Bn | 358.27 Mn | - |
| 9 | Royalty Pharma | 27.27 Bn | 26.43 Bn | - | - |
| 10 | Champions Oncology | 68.61 Mn | 68.61 Mn | 7.03 Mn | - |
Historic Data
Download Data| Date | Value |
|---|---|
| Apr 30, 2019 | 851,000.00 |
| Jan 31, 2019 | 733,000.00 |
| Oct 31, 2018 | 669,000.00 |
| Jul 31, 2018 | 605,000.00 |
| Apr 30, 2018 | 454,000.00 |